Nucleic Acid Armor: Fortifying RNA Therapeutics through Delivery and Targeting Innovations for Immunotherapy

• Published in: International journal of molecular sciences Vol. 25; no. 16; p. 8888
• Main Authors: Jiang, Yi, Jiang, Bolong, Wang, Zhenru, Li, Yuxi, Cheung, James Chung Wai, Yin, Bohan, Wong, Siu Hong Dexter
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15-08-2024; MDPI
• Subjects: Animals; Antibodies; antibody–oligonucleotide conjugates; Antigens; Drug Delivery Systems - methods; Drug resistance; Gene expression; HIV; Human immunodeficiency virus; Humans; Immune system; Immunotherapy; Immunotherapy - methods; Lipids; Nanoparticles; Nanoparticles - chemistry; nanotechnology; nucleic acid delivery; Nucleic Acids - administration & dosage; Nucleic Acids - chemistry; Polyethylene glycol; Protein expression; Protein synthesis; Proteins; R&D; Research & development; Review; Ribonucleic acid; RNA; RNA drugs; Vaccines; antibody–oligonucleotide conjugates; nanotechnology; nucleic acid delivery; RNA drugs; immunotherapy
• ISSN: 1661-6596; 1422-0067; 1422-0067
• DOI: 10.3390/ijms25168888

RNA is a promising nucleic acid-based biomolecule for various treatments because of its high efficacy, low toxicity, and the tremendous availability of targeting sequences. Nevertheless, RNA shows instability and has a short half-life in physiological environments such as the bloodstream in the presence of RNAase. Therefore, developing reliable delivery strategies is important for targeting disease sites and maximizing the therapeutic effect of RNA drugs, particularly in the field of immunotherapy. In this mini-review, we highlight two major approaches: (1) delivery vehicles and (2) chemical modifications. Recent advances in delivery vehicles employ nanotechnologies such as lipid-based nanoparticles, viral vectors, and inorganic nanocarriers to precisely target specific cell types to facilitate RNA cellular entry. On the other hand, chemical modification utilizes the alteration of RNA structures via the addition of covalent bonds such as N-acetylgalactosamine or antibodies (antibody-oligonucleotide conjugates) to target specific receptors of cells. The pros and cons of these technologies are enlisted in this review. We aim to review nucleic acid drugs, their delivery systems, targeting strategies, and related chemical modifications. Finally, we express our perspective on the potential combination of RNA-based click chemistry with adoptive cell therapy (e.g., B cells or T cells) to address the issues of short duration and short half-life associated with antibody-oligonucleotide conjugate drugs.